#1 Clinical Trials Search in Europe

Relugolix

Relugolix is an oral medication being studied in clinical trials for the treatment of prostate cancer and uterine fibroids. This article summarizes key findings from several clinical trials evaluating the safety and efficacy of relugolix for these conditions. The trials have shown promising results in suppressing testosterone levels in prostate cancer patients and reducing symptoms in women with uterine fibroids.

Table of Contents

What is Relugolix?

Relugolix is a medication that belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) receptor antagonists. It is also known by several other names, including TAK-385, MVT-601, RVT-601, T-1331285, and ORGOVYX[1]. Relugolix is primarily used to treat certain hormonal conditions and cancers that are influenced by sex hormones.

How Relugolix Works

Relugolix works by blocking the action of GnRH in the body. GnRH is a hormone that plays a crucial role in regulating the production of sex hormones like testosterone and estrogen. By blocking GnRH, Relugolix can effectively lower the levels of these hormones in the body[2]. This mechanism of action is particularly useful in treating conditions that are driven or worsened by high levels of sex hormones.

Conditions Treated with Relugolix

Relugolix has been studied and approved for use in several conditions:

  • Prostate Cancer: Relugolix is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer[3]. It helps to lower testosterone levels, which can slow down the growth of prostate cancer cells.
  • Uterine Fibroids: Relugolix has shown efficacy in treating heavy menstrual bleeding associated with uterine fibroids. Uterine fibroids are non-cancerous growths in the uterus that can cause heavy bleeding and pain[4].
  • Endometriosis: While not explicitly mentioned in the provided trials, Relugolix is being studied for its potential in managing endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus.

How Relugolix is Administered

Relugolix is typically administered as an oral tablet. The dosage and frequency can vary depending on the condition being treated:

  • For prostate cancer, a common dosage is 120 mg taken orally once daily, often starting with a loading dose of 360 mg on the first day[1].
  • For uterine fibroids, a dosage of 40 mg once daily has been studied[5].

It’s important to note that the exact dosage and duration of treatment should always be determined by a healthcare provider based on individual patient factors.

Efficacy of Relugolix

Clinical trials have demonstrated the effectiveness of Relugolix in various conditions:

  • Prostate Cancer: Relugolix has shown the ability to rapidly suppress testosterone levels to below 50 ng/dL, which is considered the castrate level. This suppression is crucial in slowing the progression of prostate cancer[2].
  • Uterine Fibroids: In studies, Relugolix has been effective in reducing heavy menstrual bleeding associated with uterine fibroids. A significant percentage of women achieved a menstrual blood loss volume of less than 80 mL and at least a 50% reduction from baseline[4].

Potential Side Effects

Like all medications, Relugolix can cause side effects. Some of the potential side effects observed in clinical trials include:

  • Hot flashes
  • Fatigue
  • Constipation
  • Diarrhea
  • Joint pain
  • Decreased libido
  • Changes in bone mineral density

It’s important to discuss potential side effects with your healthcare provider. They can provide more detailed information and help manage any side effects that may occur[6].

Ongoing Research

Relugolix continues to be the subject of ongoing research to further understand its benefits and potential applications:

  • Combination Therapies: Studies are exploring the use of Relugolix in combination with other medications. For example, a study is investigating the combination of Relugolix with darolutamide in treating prostate cancer[3].
  • Quality of Life Impact: Researchers are studying how Relugolix affects patients’ quality of life compared to other treatments. This includes assessing factors like fatigue, sexual function, and overall well-being[6].
  • Long-term Effects: Studies are also looking at the long-term effects of Relugolix, including how quickly testosterone levels return to normal after stopping treatment[3].
  • Pregnancy Registry: A pregnancy registry has been established to monitor the safety of Relugolix exposure during pregnancy[7].

These ongoing studies will help to further refine the use of Relugolix and potentially expand its applications in treating hormone-sensitive conditions.

Condition Key Findings Dosage Comparators Main Outcomes
Prostate Cancer Effective testosterone suppression, comparable to leuprolide 80 mg or 120 mg daily Leuprolide, Placebo Testosterone levels, PSA response, Quality of life
Uterine Fibroids Significant reduction in menstrual blood loss 40 mg daily Placebo, Leuprolide Menstrual blood loss, Fibroid volume, Quality of life
Safety Profile Generally well-tolerated, monitoring for bone density changes Varies by condition Standard treatments Adverse events, Vital signs, Laboratory tests
Ongoing Research Combination therapies, long-term effects, pregnancy registry Various Multiple Efficacy, Safety, Pharmacokinetics

FAQ

  • What is relugolix and how does it work? Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by blocking GnRH receptors in the pituitary gland, which reduces the production of sex hormones like testosterone and estrogen. This makes it useful for treating hormone-sensitive conditions like prostate cancer and uterine fibroids.
  • What conditions is relugolix being studied to treat? Clinical trials are evaluating relugolix for the treatment of advanced prostate cancer and uterine fibroids. It has shown effectiveness in suppressing testosterone in men with prostate cancer and reducing heavy menstrual bleeding in women with uterine fibroids.
  • How is relugolix administered in clinical trials? In most trials, relugolix is given as a daily oral tablet. Some studies use a loading dose (higher initial dose) followed by a lower maintenance dose. For prostate cancer, doses of 80 mg or 120 mg daily have been studied. For uterine fibroids, a 40 mg daily dose is common.
  • What are some of the main outcomes being measured in relugolix clinical trials? Key outcomes include testosterone suppression in prostate cancer trials and reduction in menstrual blood loss for uterine fibroid trials. Other measures include PSA levels, tumor size, quality of life scores, and safety/side effect profiles.
  • How does relugolix compare to existing treatments in clinical trials? Some trials have compared relugolix to leuprolide, an established prostate cancer treatment. Relugolix has shown similar efficacy in testosterone suppression with potential advantages in cardiovascular side effects and recovery of testosterone levels after stopping treatment. For uterine fibroids, relugolix is being compared to placebo and has shown significant reductions in menstrual blood loss.

Ongoing Clinical Trials on Relugolix

  • Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +4

  • Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Poland +1

  • Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

Glossary

  • Gonadotropin-releasing hormone (GnRH) receptor antagonist: A type of drug that blocks GnRH receptors in the pituitary gland, reducing the production of sex hormones like testosterone and estrogen.
  • Androgen deprivation therapy (ADT): A prostate cancer treatment that reduces levels of male hormones in the body to slow or stop the growth of prostate cancer cells.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland. PSA levels in the blood can be used to help detect prostate cancer and monitor treatment effectiveness.
  • Uterine fibroids: Non-cancerous growths that develop in the uterus. They can cause heavy menstrual bleeding, pain, and other symptoms.
  • Pictorial Blood Loss Assessment Chart (PBAC): A tool used to measure menstrual blood loss by having patients record their use of sanitary products and blood clots.
  • Testosterone suppression: Lowering testosterone levels in the body, often to below 50 ng/dL, which is a goal of some prostate cancer treatments.
  • Quality of life (QoL): A measure of a person's overall well-being and ability to function in daily life, often assessed using questionnaires in clinical trials.
  • Treatment-emergent adverse event (TEAE): Any unfavorable medical occurrence that begins or worsens after starting a treatment in a clinical trial.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.

References

  1. https://clinicaltrials.gov/study/NCT05467176
  2. https://clinicaltrials.gov/study/NCT02083185
  3. https://clinicaltrials.gov/study/NCT06463457
  4. https://clinicaltrials.gov/study/NCT06671548
  5. https://clinicaltrials.gov/study/NCT02655224
  6. https://clinicaltrials.gov/study/NCT05765500
  7. https://clinicaltrials.gov/study/NCT05739123